

Genoscience Pharma receives FDA approval for Phase Ib/IIa study of GNS561 in liver cancer

Nosopharm bolsters supervisory board
GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget

Imcyse continues patient enrolment in its Phase 1b trial in type 1 diabetes

AELIX Therapeutics appoints Dr. Thomas Hecht as chairman of the board of directors

Mutabilis joins the European ENABLE consortium to fight antibiotic resistance

GamaMabs and MedImmune Enter Licensing Agreement to Develop ADC Targeting Cancer

Alma Bio Therapeutics welcomes Dr. Pierre A. Morgon as member of the board of directors
